Literature DB >> 16493434

Risk factors and clinical outcomes of pulmonary interstitial emphysema in extremely low birth weight infants.

R P Verma1, S Chandra, R Niwas, E Komaroff.   

Abstract

OBJECTIVE: We studied the ante- and postnatal risk factors and clinical outcomes associated with pulmonary interstitial emphysema (PIE) in extremely low birth weight infants (ELBW, <1000 g at birth) in the present era of tocolytics, antenatal steroid and postnatal surfactant administration. STUDY
DESIGN: This was a retrospective case-controlled study of all ELBW admitted consecutively during a designated study-period in a level III nursery. Data were analyzed by performing univariate and multivariate analysis as applicable.
RESULTS: Infants with PIE had lower 1 and 5 min Apgar scores (P=0.04 and 0.003 respectively), increased surfactant utilization (P=0.004), higher maximum inspired oxygen concentration (P=0.04) and mean airway pressure administration (P=0.02) during the first week of life, and increased neonatal mortality (P=0.01). They received higher antenatal doses of magnesium sulfate (MgSO(4)) (P=0.02). 56% of infants with PIE were exposed to more than 10 g of MgSO(4) (Mg10), compared to 15% in non-PIE group (P=0.01). The multivariate logistic regression analysis including significant co-variates revealed an independent association between Mg10 and PIE (P=0.01, Odds ratio 19.8, 95% CI 1.5-263).
CONCLUSION: Pulmonary interstitial emphysema is associated with increased mortality in ELBW infants. Mg10 is an independent risk factor for PIE in this population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493434     DOI: 10.1038/sj.jp.7211456

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  8 in total

1.  Refractory Pulmonary Interstitial Emphysema in Extreme Premature Newborn.

Authors:  Mahmoud Ali; Lea Mallett; Greg Miller
Journal:  AJP Rep       Date:  2021-05-27

2.  A Case of Pulmonary Interstitial Emphysema Treated by Percutaneous Catheter Insertion in Extremely Low Birth Weight Infant.

Authors:  Changsin Kim; Jeong Eun Shin; Soon Min Lee; Ho Seon Eun; Min Soo Park; Kook In Park; Ran Namgung; Sungsoo Lee; Choon Sik Yoon
Journal:  Yonsei Med J       Date:  2016-11       Impact factor: 2.759

3.  Lobectomy with ECMO Support in an Infant Who Developed Pulmonary Interstitial Emphysema Following Repair of Hypoplastic Aortic Arch.

Authors:  Michael Magarakis; Dao M Nguyen; Alejandro E Macias; Eliot R Rosenkranz
Journal:  Braz J Cardiovasc Surg       Date:  2018 Sep-Oct

4.  Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis.

Authors:  Emily Shepherd; Rehana A Salam; Deepak Manhas; Anne Synnes; Philippa Middleton; Maria Makrides; Caroline A Crowther
Journal:  PLoS Med       Date:  2019-12-06       Impact factor: 11.069

5.  Persistent Pulmonary Interstitial Emphysema With Respiratory Infection: A Clinicopathological Analysis of Six Cases and Detection of Infectious Pathogens by Metagenomic Next-Generation Sequencing (mNGS).

Authors:  Ping Zhou; Weiya Wang; Yiyun Fu; Ying Zhang; Zuoyu Liang; Yuan Tang; Lili Jiang
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.418

6.  Development of Localized Pulmonary Interstitial Emphysema in a Late Preterm Infant without Mechanical Ventilation.

Authors:  Pritish Bawa; Kultida Soontarapornchai; Agnes Perenyi; Rachelle Goldfisher; John Amodio
Journal:  Case Rep Pediatr       Date:  2014-03-11

7.  Early Pulmonary Interstitial Emphysema in Preterm Neonates-Respiratory Management and Case Report in Nonventilated Very Low Birth Weight Twins.

Authors:  Judith Gronbach; Harald Ehrhardt; Klaus-Peter Zimmer; Markus Waitz
Journal:  AJP Rep       Date:  2018-05-14

Review 8.  Positional treatment without mechanical ventilation in a very preterm infant with unilateral pulmonary interstitial emphysema: case report and review of the literature.

Authors:  Xiaoping Lei; Oliver Stangl; Christina Bösche; Kristina Stuchlik; Roland Czorba; Christian Wieg
Journal:  BMC Pediatr       Date:  2019-08-01       Impact factor: 2.125

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.